<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tassopoulos, N. C.</style></author><author><style face="normal" font="default" size="100%">Ketikoglou, I.</style></author><author><style face="normal" font="default" size="100%">Tsantoulas, D.</style></author><author><style face="normal" font="default" size="100%">Raptopoulou, M.</style></author><author><style face="normal" font="default" size="100%">Hatzis, G.</style></author><author><style face="normal" font="default" size="100%">Vafiadis, I.</style></author><author><style face="normal" font="default" size="100%">Sidiropoulos, L.</style></author><author><style face="normal" font="default" size="100%">Kanatakis, S.</style></author><author><style face="normal" font="default" size="100%">Anagnostopoulos, G.</style></author><author><style face="normal" font="default" size="100%">Sypsa, V</style></author><author><style face="normal" font="default" size="100%">Hatzakis, A</style></author><author><style face="normal" font="default" size="100%">Hellenic Viral Hepatitis Research, Network</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A randomized trial to assess the efficacy of interferon-alpha daily in combination with ribavirin in the treatment of naive patients with chronic hepatitis C</style></title><secondary-title><style face="normal" font="default" size="100%">J Viral HepatJ Viral HepatJ Viral Hepat</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of viral hepatitis</style></alt-title><short-title><style face="normal" font="default" size="100%">Journal of viral hepatitisJournal of viral hepatitis</style></short-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Antiviral Agents/administration &amp; dosage/*therapeutic use</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Hepacivirus/genetics/*isolation &amp; purification</style></keyword><keyword><style  face="normal" font="default" size="100%">Hepatitis C, Chronic/*drug therapy/virology</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Interferon-alpha/administration &amp; dosage/*therapeutic use</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Ribavirin/administration &amp; dosage/*therapeutic use</style></keyword><keyword><style  face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style  face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style  face="normal" font="default" size="100%">Viral Load</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2003</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">5</style></number><volume><style face="normal" font="default" size="100%">10</style></volume><pages><style face="normal" font="default" size="100%">383-9</style></pages><isbn><style face="normal" font="default" size="100%">1352-0504 (Print)1352-0504 (Linking)</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">A randomized trial was conducted to assess the efficacy of interferon-alpha (IFN) daily in combination with ribavirin in 301 naive patients with chronic hepatitis C (CHC). Patients were randomized to receive ribavirin 1.2 g daily (QD) for 48 weeks with either IFN 5 MU (thrice weekly) TIW for 8 weeks followed by IFN 3 MU TIW for 40 weeks (IFN TIW, n = 154) or IFN 5 MU QD for 8 weeks followed by IFN 3 MU QD for 16 weeks followed by IFN 3 MU TIW for 24 weeks (IFN QD, n = 147). Treatment discontinuation rates, because of adverse events, were similar in the two arms (14.9% in IFN TIW and 14.3% in IFN QD, P = 0.87). The proportion of patients with sustained virological response (SVR) was 27.9% for patients treated TIW and 38.8% for those treated QD (P = 0.046). According to logistic regression analysis, patients in the IFN QD arm had 1.7 times higher probability of achieving SVR, than those receiving IFN TIW (P = 0.038). Low baseline viral load (P = 0.017) and genotype non-1 (P = 0.036) were associated with higher SVR rates. Combination of IFN/ribavirin for 48 weeks is more effective when IFN is administered daily for the first 24 weeks in naive patients with CHC.</style></abstract><accession-num><style face="normal" font="default" size="100%">12969190</style></accession-num><notes><style face="normal" font="default" size="100%">Tassopoulos, N CKetikoglou, ITsantoulas, DRaptopoulou, MHatzis, GVafiadis, ISidiropoulos, LKanatakis, SAnagnostopoulos, GSypsa, VHatzakis, AengClinical TrialRandomized Controlled TrialResearch Support, Non-U.S. Gov'tEngland2003/09/13 05:00J Viral Hepat. 2003 Sep;10(5):383-9. doi: 10.1046/j.1365-2893.2003.00439.x.</style></notes><auth-address><style face="normal" font="default" size="100%">Western Attica General Hospital, Athens; Hippokration General Hospital, Athens, Greece.</style></auth-address></record></records></xml>